$2.27
+0.15(7.31%)
Mkt Cap $45M
$1.22
$5.10
52-Week Range
At a Glance
AI-generatedAnnovis Bio, Inc.
8-K
Annovis Bio, Inc. disclosed that Mark Guerin is no longer employed as Chief Financial Officer effective March 23, 2026, with no disagreement on operations, policies, or practices. The board anticipates appointing Maria Maccecchini, the Chief Executive Officer, as Acting Chief Financial Officer until a replacement is identified.$45M
Market Cap
—
Revenue
-$23M
Net Income
Employees8
Fundamentals
How The Business Makes Money
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the traumatic brain injury and stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.
Industry Biotechnology
Activity
What Changed Recently
Analyst View
Company Profile
CIK0001477845
ISINUS03615A1088
CUSIP03615A108
Phone610 727 3913
Address1055 Westlakes Drive, Malvern, PA, 19312, US
SEC EDGAR